


# OUR PIPELINE

LAST UPDATED: OCTOBER 7, 2024

We are building a pipeline of *in vivo* and *ex vivo* therapies, as well as continuing to develop innovative modular platform capabilities.

## IN VIVO PROGRAMS

**IN VIVO** CRISPR **is** the therapy  
**GENETIC DISEASES**



## EX VIVO PROGRAMS

**EX VIVO** CRISPR **creates** the therapy  
**IMMUNO-ONCOLOGY / AUTOIMMUNE DISEASE**



AATD: Alpha-1 Antitrypsin Deficiency

Lead refers to lead development and commercial party.

\* Intellia is advancing both wholly-owned and partnered programs.

\*\* NTLA-2001 is now known as nexiguran ziclumeran (nex-z)

\*\*\* Hemophilia A program is in the research stage. Hemophilia B is being advanced by Regeneron. Intellia is eligible for milestones and royalties.